Everyday bladder, sleep and allergy pills are tied to about 50 per cent higher dementia odds

A decade-long study of older adults has found that people who accumulate heavy use of a broad category of medications known as anticholinergics, drugs commonly prescribed for overactive bladder, seasonal allergies, depression and sleep problems, face meaningfully higher odds of developing dementia than people who rarely or never take them. Among the heaviest users in the study, the increase in risk reached about 50 per cent compared with people who had taken none of these drugs at all.

One Mechanism Behind Many Everyday Pills

Anticholinergic drugs work by blocking the neurotransmitter acetylcholine, which the body uses to send signals both in the brain and in organs such as the bladder and gut. That mechanism is exactly why the drugs are useful for so many different conditions: blocking acetylcholine calms an overactive bladder, dries up allergy symptoms, and can ease depression or promote sleep, depending on the specific medication. Some are available over the counter as sleep aids. The tradeoff has long been recognised in short-term use, since blocking acetylcholine in the brain can cause confusion, drowsiness and memory lapses, particularly in older adults. Doctors have generally treated that impairment as reversible once someone stops the medication, which is part of why the possibility of a lasting, cumulative effect drew researchers’ attention.

Tracking Pharmacy Records for 3,434 Adults

Researchers at the University of Washington School of Pharmacy, working with the Group Health Research Institute in Seattle, used computerised pharmacy dispensing records from the Adult Changes in Thought study to calculate cumulative anticholinergic exposure for 3,434 adults aged 65 and older who had no dementia at the start of the study. Rather than simply asking whether someone had ever taken one of these drugs, the researchers totalled the standardised daily doses dispensed over the prior ten years for each participant, then tracked who went on to develop dementia over an average of more than seven years of follow-up.

A Clear Dose-Response Pattern

Seventy-eight per cent of participants had filled at least one prescription for a strong anticholinergic drug within the ten-year window, and 797 people, or 23 per cent, eventually developed dementia, most commonly Alzheimer’s disease. Risk rose in step with cumulative dose rather than appearing all at once. People in the lowest exposure category showed no meaningful increase in risk, but those in the highest category, equivalent to taking a single strong anticholinergic drug daily at its minimum effective dose for more than three years, had an adjusted risk of dementia about 50 per cent higher, and a 63 per cent higher risk of Alzheimer’s disease specifically, compared with people who had taken none of these drugs at all. The middle exposure categories fell in between, forming a step-by-step climb rather than a single threshold effect.

Doxepin, Chlorpheniramine and Oxybutynin

The medications driving most of that exposure fell into three everyday categories: antidepressants, first-generation antihistamines and bladder antimuscarinic drugs, which together accounted for more than 90 per cent of all anticholinergic use recorded in the study. The most commonly used individual drugs in those categories were doxepin, a tricyclic antidepressant also prescribed at low doses as a sleep aid, chlorpheniramine, an older antihistamine used for seasonal allergies, and oxybutynin, prescribed for an overactive bladder. Researchers specifically tested whether the pattern was simply an artefact of treating depression, itself an early symptom of undiagnosed dementia, by separating antidepressants from every other anticholinergic class in a follow-up analysis. The elevated risk showed up in both groups, not just among antidepressant users, which argues against the idea that the entire association is explained by people already showing early, undiagnosed symptoms of the disease. Because several older antihistamines are sold over the counter, the researchers noted that some allergy and sleep-aid use could have gone uncounted if people bought products outside their regular pharmacy, meaning the true cumulative exposure for some participants may have been even higher than the records captured.

A Risk That Did Not Fade With Time

One further finding, detailed in the published study, stood out: among the heaviest users, people whose exposure came mostly from years in the past carried a similar risk to those who were still taking the drugs at the time of diagnosis. That pattern runs counter to the long-standing assumption that anticholinergic-related cognitive effects simply reverse once the medication stops. The association also held up regardless of sex and did not depend on carrying the APOE ε4 gene variant that is itself linked to higher Alzheimer’s risk, suggesting the pattern was not simply concentrated in people who were already genetically predisposed. Researchers pointed to animal studies and a small autopsy study of Parkinson’s patients on anticholinergic drugs, which found more Alzheimer’s-related brain changes among long-term users, as early evidence that the mechanism is biologically plausible rather than a statistical coincidence. The study cannot prove that these drugs cause dementia, since it remains an observational analysis that cannot rule out every unmeasured factor, and the researchers themselves called for further work to confirm the findings and clarify the underlying biology. Their practical recommendation is not to stop a prescribed medication abruptly, but for older adults and their doctors to periodically review long-term anticholinergic use, weigh it against the available alternatives, and use the lowest effective dose when one of these drugs is genuinely needed.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview